The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells
2005

Medroxyprogesterone Acetate and Its Effects on Breast Cancer Cells

publication Evidence: moderate

Author Information

Author(s): Ghatge Radhika P, Jacobsen Britta M, Schittone Stephanie A, Horwitz Kathryn B

Primary Institution: University of Colorado Health Sciences Center

Hypothesis

Is the increased breast cancer risk associated with medroxyprogesterone acetate (MPA) due to its progestational or androgenic properties?

Conclusion

MPA exhibits both progestational and androgenic properties in breast cancer cells, suggesting that its effects do not mimic those of endogenous progesterone alone.

Supporting Evidence

  • MPA was found to be an effective progestin in progesterone receptor-positive cells.
  • Gene regulatory overlap was observed between MPA and dihydrotestosterone through androgen receptors.
  • High-dose therapeutic MPA may be unnecessary as there was no difference between pharmacological and physiological MPA.

Takeaway

This study found that a hormone called MPA can act like two different hormones in breast cancer cells, which might affect how it works in treatments.

Methodology

The study involved engineering a new breast cancer cell line and performing transcription assays and gene expression profiling to compare the effects of MPA, progesterone, and dihydrotestosterone.

Limitations

The study is limited to short-term treatments in vitro.

Statistical Information

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/bcr1340

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication